Sentences with word «imatinib»

Phase II, open - label, single - arm trial of imatinib mesylate in patients with metastatic melanoma harboring c - Kit mutation or amplification.

The 10 - year survival rate in subjects receiving first - line treatment with imatinib ranged from 64.4 % to 84.4 %.

[44] Two other phase II clinical trials evaluated the efficacy of imatinib in patients with melanoma — including mucosal melanomas — harboring KIT mutations and / or amplifications, with a subset of cases involving mucosal primaries, and both found a disease control rate of approximately 50 %.

The drug imatinib mesylate (Gleevec) is shown to be effective against chronic myelogenous leukemia (CML).

A new study shows that the cancer drugs imatinib (also known as Gleevec by Novartis) and sunitinib (Sutent, made by Pfizer) halt diabetes in mice.

[12] It was marketed in 2001 by Novartis as imatinib mesylate (Gleevec in the US, Glivec in Europe).

Ghalaut VS, Sangwan L, Dahiya K, Ghalaut PS, Dhankhar R, Saharan R. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia.

This knowledge laid the foundation for the targeted cancer treatment revolution inaugurated by imatinib (Gleevec ®), which has made another blood cancer, chronic myelogenous leukemia, a controllable, chronic disease for many patients.

In future, it may be possible to measure BCR - ABL levels in individual cells in the clinic — this will help us identify the resistant high BCR - ABL cells and better understand how patients develop resistance to imatinib treatment with the aim of combatting this resistance to make response more durable and the treatment more effective.»

Contrary to previous laboratory findings, a new study has shown for the first time the effect of stem cell burden on treatment outcome, discovering that tyrosine kinase inhibitors, including imatinib and dasatinib, can rapidly eradicate most chronic myeloid leukemia stem cells.

Novartis unbelievably went as far as paying specialty pharmacies to recommend Tasigna to Medicare and Medicaid patients who were trying to fill prescriptions for other drugs (potentially generic imatinib) and to downplay the side effects of Tasigna to patients considering switching drugs.

Our structural analysis enables us to understand why GNF - 5 contributes to overcome imatinib resistance,» explains Lukasz Skora, a former postdoc from Stephan Grzesiek's lab.

After completing a series of preclinical studies, Dr. Druker spearheaded the highly successful clinical trials of imatinib for CML, which led to FDA approval of the drug in record time.

The use of alternative KIT inhibitors following progression on imatinib has achieved clinical benefit in patients with advanced GIST.

The adenosine triphosphate (ATP)-- competitive kinase inhibitors imatinib (STI571; trade name: Gleevec), dasatinib, and nilotinib inhibit multiple tyrosine kinases in addition to ABL1 and ABL2 (5).

The researchers have shown that the binding of imatinib unexpectedly shifts this equilibrium to the open state.

«Although TKIs such as the first - generation TKI imatinib mesylate (IM) and the second - generation TKIs dasatinib and nilotinib have markedly improved the prognosis of patients with chronic phase CML, a cure remains elusive.

The mice lived longer than control mice; 30 percent lived longer than 80 days compared to mice treated with only imatinib, all of which died within 60 days.

The team tested a combination of PGE1 and the TKI drug called imatinib in a mouse model of CML.

When the mice received no treatment or were treated with imatinib alone, the human leukemia stem cells propagated and grew to relatively large numbers.

After a median follow - up period of 36 months, three patients randomized to continue treatment (17 %) and 10 patients in the discontinuation arm (67 %) had a molecular relapse; all three of the former patients had stopped imatinib treatment after randomization.

Studies here are probing questions such as whether and for how long imatinib should be taken after surgical removal of GIST tumors.

Patients who are unable to undergo surgery will generally receive treatment with imatinib until their tumor becomes resistant to that drug, then other agents are offered.

In one report, a patient with an L576P KIT mutation in whom imatinib therapy had previously failed experienced marked reduction in tumor burden in response to dasatinib treatment.

Geminin overexpression promotes imatinib sensitive breast cancer: A novel treatment approach for aggressive breast cancers, including a subset of triple negative

Several targeted drugs (e.g., imatinib [Gleevec ®], dasatinib [Sprycel ®]-RRB- are effective for treating CML because they attack cells with the Philadelphia chromosome, the genetic abnormality that is the hallmark of this type of leukemia.

Here patients treated with imatinib become resistant because of the acquisition of mutations in the ABL kinase domain.13

Citing a hypothetical scenario, Teva claimed that if marketing authorization for nilotinib was granted in November 2011, then the interpretation adopted by EMA would have prevented imatinib generic filings until November 2021, i.e. for twenty years from its first marketing authorization date.

In its second line of argument, Teva stated that the incorrect interpretation of Article 8 has the effect of unjustifiably extending orphan exclusivity of imatinib beyond the ten - year period and consequently denying it the opportunity to submit application and obtain approval for a generic equivalent.

The analysis suggests that patients with complex indels in KIT would benefit from drugs such as imatinib, sunitnib and sorafenib, which target mutations in this gene.

He has played a key role in the discovery and development of multiple approved drugs, including imatinib (Gleevec), dasatinib (Sprycel), and enzalutamide (Xtandi).

Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia

Ninety - five percent of affected patients can be treated successfully with the Novartis drug imatinib, also known as Gleevec ®.

However, the General Court upheld the EMA's decision refusing Teva's generic application for imatinib in view of nilotinib's orphan drug exclusivity pertaining to CML.

«To our knowledge, this is the first randomized trial regarding the discontinuation of imatinib in first chronic phase CML patients who have achieved a durable and stable molecular response,» the authors wrote.

Patients with CML who have higher proportions of natural killer immune cells, and more mature natural killer cells, fare better when discontinuing therapy with imatinib.

The allosteric inhibitor GNF - 5, however, stabilizes the closed, inactivated state, and even recloses the imatinib - induced open state.

Five percent of all patients are not cured by imatinib However, in five percent of CML patients, typically in an advanced stage of the disease, imatinib and similar ATP - binding site inhibitors are not effective.

The current study showed that HIF - 1α inhibitors, specifically the cancer drug imatinib (Gleevec), the natural product apigenin, and the small molecule PX - 478, potently inhibit dysregulated BMP signaling induced by HIF - 1α in cells, as well as heterotopic ossification following tissue injury in a mouse model of FOP.

These stickier cells were less sensitive to treatment with a BCR - ABL targeted drug, imatinib.

In contrast, when the animals were treated with a combination of imatinib and PGE1, those numbers were greatly reduced, and mice did not develop leukemia.

• A patient's undifferentiated small bowel sarcoma was found to contain a KIT gene deletion, resulting in a revised diagnosis of GIST (gastrointestinal stromal tumor) that was successfully treated with imatinib.

The trio was integral in developing the drugs imatinib and dasatinib, which shut down certain proteins that are responsible for the rapid division of cancer cells.

• A patient with blood cancer who had received several diagnoses was found, through testing, to have an unusual form of acute myeloid leukemia (AML), which predicted responsiveness to imatinib.

Novartis AG's (NYSE: NVS) drug Gleevec (imatinib), which targets a fusion protein responsible for CML, has proved to be highly effective in arresting the disease.

[13] The T315I mutation in the fusion gene confers resistance to other tyrosine kinase inhibitors such as imatinib, however axitinib has been successfully been used to treat a patient with ALL carrying this mutation, as well as CML cells in culture.

New inhibitors include dasatinib and nilotinib, which are significantly more potent than imatinib and may overcome resistance.